Compare Msci Inc (MSCI) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs Recursion Pharmaceuticals Inc — how do they compare? Msci Inc trades at $564.93 (market cap $40.38B), while Recursion Pharmaceuticals Inc trades at $4.39 (market cap $2.14B). The key difference: Msci Inc is far larger — about 18.9× Recursion Pharmaceuticals Inc's market cap, and Msci Inc pays a 1.48% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Msci Inc for 82 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| MSCI | RXRX | |
|---|---|---|
Market Cap | $40.38B | $2.14B |
Volume | 414,140 | 30,789,535 |
Sector | Financials | Health |
52-Week High | $643.83 | $6.79 |
52-Week Low | $511.84 | $2.84 |
Typical Hold Time | 82 Days | 22 Days |
Enterprise Value | $46.54B | $1.66B |
Dividend Yield | 1.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSCI trades at $565.05, up 1.74% on the day, with a neutral technical signal and key resistance near $567. The company reported Q2 2026 earnings of $4.94 per share, slightly missing estimates, but maintains strong fundamentals with 40.73% net income margin and revenue growth to $3.13 billion in 2025. Recent news includes the completion of the First Street acquisition and upcoming Q3 2026 earnings call.
The outlook is supported by high analyst bullishness (74% buy ratings) and a consensus price target of $701.71, implying significant upside. Risks include high valuation multiples (P/E 30.37) and substantial long-term debt of $4.51 billion. Earnings growth and execution on strategic acquisitions are critical for sustaining momentum.
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
